Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Abigail Collins is active.

Publication


Featured researches published by Abigail Collins.


Nature Genetics | 2014

Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling

Gillian I. Rice; Yoandris del Toro Duany; Emma M. Jenkinson; Gabriella M.A. Forte; Beverley Anderson; Giada Ariaudo; Brigitte Bader-Meunier; Roberta Battini; Michael W. Beresford; Manuela Casarano; Mondher Chouchane; Rolando Cimaz; Abigail Collins; Nuno J V Cordeiro; Russell C. Dale; Joyce Davidson; Liesbeth De Waele; Isabelle Desguerre; Laurence Faivre; Elisa Fazzi; Bertrand Isidor; Lieven Lagae; Andrew Latchman; Pierre Lebon; Chumei Li; John H. Livingston; Charles Marques Lourenço; Maria Margherita Mancardi; Alice Masurel-Paulet; Iain B. McInnes

The type I interferon system is integral to human antiviral immunity. However, inappropriate stimulation or defective negative regulation of this system can lead to inflammatory disease. We sought to determine the molecular basis of genetically uncharacterized cases of the type I interferonopathy Aicardi-Goutières syndrome and of other undefined neurological and immunological phenotypes also demonstrating an upregulated type I interferon response. We found that heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state. Cellular and biochemical assays indicate that these mutations confer gain of function such that mutant IFIH1 binds RNA more avidly, leading to increased baseline and ligand-induced interferon signaling. Our results demonstrate that aberrant sensing of nucleic acids can cause immune upregulation.


Movement Disorders | 2010

DEFINITION AND CLASSIFICATION OF HYPERKINETIC MOVEMENTS IN CHILDHOOD

Terence D. Sanger; Daofen Chen; Darcy Fehlings; Mark Hallett; Anthony E. Lang; Jonathan W. Mink; Harvey S. Singer; Katharine E. Alter; Erin E. Butler; Robert Chen; Abigail Collins; Sudarshan Dayanidhi; Hans Forssberg; Eileen Fowler; Donald L. Gilbert; Sharon L. Gorman; Mark Gormley; H.A. Jinnah; Barbara L. Kornblau; Kristin J. Krosschell; Rebecca K. Lehman; Colum D. MacKinnon; C. J. Malanga; Ronit Mesterman; Margaret Barry Michaels; Toni S. Pearson; Jessica Rose; Barry S. Russman; Dagmar Sternad; K.J. Swoboda

Hyperkinetic movements are unwanted or excess movements that are frequently seen in children with neurologic disorders. They are an important clinical finding with significant implications for diagnosis and treatment. However, the lack of agreement on standard terminology and definitions interferes with clinical treatment and research. We describe definitions of dystonia, chorea, athetosis, myoclonus, tremor, tics, and stereotypies that arose from a consensus meeting in June 2008 of specialists from different clinical and basic science fields. Dystonia is a movement disorder in which involuntary sustained or intermittent muscle contractions cause twisting and repetitive movements, abnormal postures, or both. Chorea is an ongoing random‐appearing sequence of one or more discrete involuntary movements or movement fragments. Athetosis is a slow, continuous, involuntary writhing movement that prevents maintenance of a stable posture. Myoclonus is a sequence of repeated, often nonrhythmic, brief shock‐like jerks due to sudden involuntary contraction or relaxation of one or more muscles. Tremor is a rhythmic back‐and‐forth or oscillating involuntary movement about a joint axis. Tics are repeated, individually recognizable, intermittent movements or movement fragments that are almost always briefly suppressible and are usually associated with awareness of an urge to perform the movement. Stereotypies are repetitive, simple movements that can be voluntarily suppressed. We provide recommended techniques for clinical examination and suggestions for differentiating between the different types of hyperkinetic movements, noting that there may be overlap between conditions. These definitions and the diagnostic recommendations are intended to be reliable and useful for clinical practice, communication between clinicians and researchers, and for the design of quantitative tests that will guide and assess the outcome of future clinical trials.


PLOS ONE | 2015

Alternating hemiplegia of childhood: Retrospective genetic study and genotype-phenotype correlations in 187 subjects from the US AHCF registry

Louis Viollet; Gustavo Glusman; Kelley J. Murphy; Tara M. Newcomb; Sandra P. Reyna; Matthew T. Sweney; Benjamin Nelson; Frederick Andermann; Eva Andermann; Gyula Acsadi; Richard L. Barbano; Candida Brown; Mary E. Brunkow; Harry T. Chugani; Sarah R. Cheyette; Abigail Collins; Suzanne D. DeBrosse; David J. Galas; Jennifer Friedman; Lee Hood; Chad D. Huff; Lynn B. Jorde; Mary D. King; Bernie LaSalle; Richard J. Leventer; Aga J. Lewelt; Mylynda B. Massart; Mario R. Mérida; Louis J. Ptáček; Jared C. Roach

Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase. Published studies to date indicate 2 recurrent mutations, D801N and E815K, and a more severe phenotype in the E815K cohort. We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012. Clinical data were abstracted from standardized caregivers’ questionnaires and medical records and confirmed by expert clinicians. We identified ATP1A3 mutations by Sanger and whole genome sequencing, and compared phenotypes within and between 4 groups of subjects, those with D801N, E815K, other ATP1A3 or no ATP1A3 mutations. We identified heterozygous ATP1A3 mutations in 154 of 187 (82%) AHC patients. Of 34 unique mutations, 31 (91%) are missense, and 16 (47%) had not been previously reported. Concordant with prior studies, more than 2/3 of all mutations are clustered in exons 17 and 18. Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K (26%) and 11 had G937R (8%) mutations. Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus. This study further expands the number and spectrum of ATP1A3 mutations associated with AHC and confirms a more deleterious effect of the E815K mutation on selected neurologic outcomes. However, the complexity of the disorder and the extensive phenotypic variability among subgroups merits caution and emphasizes the need for further studies.


Journal of Medical Genetics | 2015

Mutations in the mitochondrial cysteinyl-tRNA synthase gene, CARS2, lead to a severe epileptic encephalopathy and complex movement disorder

Curtis R. Coughlin; Gunter Scharer; Marisa W. Friederich; Hung-Chun Yu; Elizabeth A. Geiger; Geralyn Creadon-Swindell; Abigail Collins; Arnaud Vanlander; Rudy Van Coster; Christopher A. Powell; Michael A. Swanson; Michal Minczuk; Johan L.K. Van Hove; Tamim H. Shaikh

Background Mitochondrial disease is often suspected in cases of severe epileptic encephalopathy especially when a complex movement disorder, liver involvement and progressive developmental regression are present. Although mutations in either mitochondrial DNA or POLG are often present, other nuclear defects in mitochondrial DNA replication and protein translation have been associated with a severe epileptic encephalopathy. Methods and results We identified a proband with an epileptic encephalopathy, complex movement disorder and a combined mitochondrial respiratory chain enzyme deficiency. The child presented with neurological regression, complex movement disorder and intractable seizures. A combined deficiency of mitochondrial complexes I, III and IV was noted in liver tissue, along with increased mitochondrial DNA content in skeletal muscle. Incomplete assembly of complex V, using blue native polyacrylamide gel electrophoretic analysis and complex I, using western blotting, suggested a disorder of mitochondrial transcription or translation. Exome sequencing identified compound heterozygous mutations in CARS2, a mitochondrial aminoacyl-tRNA synthetase. Both mutations affect highly conserved amino acids located within the functional ligase domain of the cysteinyl-tRNA synthase. A specific decrease in the amount of charged mt-tRNACys was detected in patient fibroblasts compared with controls. Retroviral transfection of the wild-type CARS2 into patient skin fibroblasts led to the correction of the incomplete assembly of complex V, providing functional evidence for the role of CARS2 mutations in disease aetiology. Conclusions Our findings indicate that mutations in CARS2 result in a mitochondrial translational defect as seen in individuals with mitochondrial epileptic encephalopathy.


Mitochondrion | 2014

Practice patterns of mitochondrial disease physicians in North America. Part 1: diagnostic and clinical challenges.

Sumit Parikh; Amy Goldstein; Mary Kay Koenig; Fernando Scaglia; Gregory M. Enns; Russell P. Saneto; Irina Anselm; Abigail Collins; Bruce H. Cohen; Suzanne D. DeBrosse; David Dimmock; Marni J. Falk; Jaya Ganesh; Carol L. Greene; Andrea Gropman; Richard H. Haas; Stephen G. Kahler; John Kamholz; Fran Kendall; Mark S. Korson; Andre Mattman; Margherita Milone; Dmitriy Niyazov; Phillip L. Pearl; Tyler Reimschisel; Ramona Salvarinova-Zivkovic; Katherine B. Sims; Mark A. Tarnopolsky; Chang Yong Tsao; Johan L. K. Van Hove

Mitochondrial medicine is a young subspecialty. Clinicians have a limited evidence base on which to formulate clinical decisions regarding diagnosis, treatment and patient management. Mitochondrial medicine specialists have cobbled together an informal set of rules and paradigms for preventive care and management based in part on anecdotal experience. The Mitochondrial Medicine Society (MMS) assessed the current state of clinical practice from diagnosis, to preventive care and treatment, as provided by various mitochondrial disease specialists in North America. We hope that by obtaining this information we can begin moving towards formulating a set of consensus criteria and establishing standards of care.


Mitochondrion | 2013

Practice patterns of mitochondrial disease physicians in North America. Part 2: treatment, care and management.

Sumit Parikh; Amy Goldstein; Mary Kay Koenig; Fernando Scaglia; Gregory M. Enns; Russell P. Saneto; Irina Anselm; Abigail Collins; Bruce H. Cohen; Suzanne D. DeBrosse; David Dimmock; Marni J. Falk; Jaya Ganesh; Carol Greene; Andrea Gropman; Richard H. Haas; Stephen G. Kahler; John Kamholz; Fran Kendall; Mark S. Korson; Andre Mattman; Margherita Milone; Dmitriy Niyazov; Phillip L. Pearl; Tyler Reimschisel; Ramona Salvarinova-Zivkovic; Katherine B. Sims; Mark A. Tarnopolsky; Chang-Yong Tsao; Johan L. K. Van Hove

Mitochondrial medicine is a young subspecialty. Clinicians have limited evidence-based guidelines on which to formulate clinical decisions regarding diagnosis, treatment and management for patients with mitochondrial disorders. Mitochondrial medicine specialists have cobbled together an informal set of rules and paradigms for preventive care and management based in part on anecdotal experience. The Mitochondrial Medicine Society (MMS) assessed the current state of clinical practice including diagnosis, preventive care and treatment, as provided by various mitochondrial disease providers in North America. In this second of two reports, we present data related to clinical practice that highlight the challenges clinicians face in the routine care of patients with established mitochondrial disease. Concerning variability in treatment and preventative care approaches were noted. We hope that sharing this information will be a first step toward formulating a set of consensus criteria and establishing standards of care.


Human Molecular Genetics | 2014

Mutation of senataxin alters disease-specific transcriptional networks in patients with ataxia with oculomotor apraxia type 2

Brent L. Fogel; Ellen Cho; Amanda Wahnich; Fuying Gao; Olivier J. Becherel; Xizhe Wang; Francesca Fike; Leslie Chen; Chiara Criscuolo; Giuseppe De Michele; Alessandro Filla; Abigail Collins; Angelika F. Hahn; Richard A. Gatti; Genevieve Konopka; Susan Perlman; Martin F. Lavin; Daniel H. Geschwind; Giovanni Coppola

Senataxin, encoded by the SETX gene, contributes to multiple aspects of gene expression, including transcription and RNA processing. Mutations in SETX cause the recessive disorder ataxia with oculomotor apraxia type 2 (AOA2) and a dominant juvenile form of amyotrophic lateral sclerosis (ALS4). To assess the functional role of senataxin in disease, we examined differential gene expression in AOA2 patient fibroblasts, identifying a core set of genes showing altered expression by microarray and RNA-sequencing. To determine whether AOA2 and ALS4 mutations differentially affect gene expression, we overexpressed disease-specific SETX mutations in senataxin-haploinsufficient fibroblasts and observed changes in distinct sets of genes. This implicates mutation-specific alterations of senataxin function in disease pathogenesis and provides a novel example of allelic neurogenetic disorders with differing gene expression profiles. Weighted gene co-expression network analysis (WGCNA) demonstrated these senataxin-associated genes to be involved in both mutation-specific and shared functional gene networks. To assess this in vivo, we performed gene expression analysis on peripheral blood from members of 12 different AOA2 families and identified an AOA2-specific transcriptional signature. WGCNA identified two gene modules highly enriched for this transcriptional signature in the peripheral blood of all AOA2 patients studied. These modules were disease-specific and preserved in patient fibroblasts and in the cerebellum of Setx knockout mice demonstrating conservation across species and cell types, including neurons. These results identify novel genes and cellular pathways related to senataxin function in normal and disease states, and implicate alterations in gene expression as underlying the phenotypic differences between AOA2 and ALS4.


Neurologic Clinics | 2013

Clinical Neurogenetics: Friedreich Ataxia

Abigail Collins

Friedreich ataxia is the most common autosomal recessive ataxia. It is a progressive neurodegenerative disorder, typically with onset before 20 years of age. Signs and symptoms include progressive ataxia, ascending weakness and ascending loss of vibration and joint position senses, pes cavus, scoliosis, cardiomyopathy, and arrhythmias. There are no disease-modifying medications to either slow or halt the progression of the disease, but research investigating therapies to increase endogenous frataxin production and decrease the downstream consequences of disrupted iron homeostasis is ongoing. Clinical trials of promising medications are underway, and the treatment era of Friedreich ataxia is beginning.


PLOS ONE | 2015

Erratum: Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry (PLoS ONE (2015) 10:8 (e0137370) (doi:10.1371/journal.pone.0137370))

Louis Viollet; Gustavo Glusman; Kelley J. Murphy; Tara M. Newcomb; Sandra P. Reyna; Matthew T. Sweney; Benjamin R. Nelson; Frederick Andermann; Eva Andermann; Gyula Acsadi; Richard L. Barbano; Candida Brown; Mary E. Brunkow; Harry T. Chugani; Sarah R. Cheyette; Abigail Collins; Suzanne D. DeBrosse; David J. Galas; Jennifer Friedman; Lee Hood; Chad D. Huff; Lynn B. Jorde; Mary D. King; Bernie LaSalle; Richard J. Leventer; Aga J. Lewelt; Mylynda B. Massart; Mario R. Mérida; Louis J. Ptáček; Jared C. Roach

Louis Viollet, Gustavo Glusman, Kelley J. Murphy, Tara M. Newcomb, Sandra P. Reyna, Matthew Sweney, Benjamin Nelson, Frederick Andermann, Eva Andermann, Gyula Acsadi, Richard L. Barbano, Candida Brown, Mary E. Brunkow, Harry T. Chugani, Sarah R. Cheyette, Abigail Collins, Suzanne D. DeBrosse, David Galas, Jennifer Friedman, Lee Hood, Chad Huff, Lynn B. Jorde, Mary D. King, Bernie LaSalle, Richard J. Leventer, Aga J. Lewelt, Mylynda B. Massart, Mario R. Mérida, II, Louis J. Ptáček, Jared C. Roach, Robert S. Rust, Francis Renault, Terry D. Sanger, Marcio A. Sotero de Menezes, Rachel Tennyson, Peter Uldall, Yue Zhang, Mary Zupanc, Winnie Xin, Kenneth Silver, Kathryn J. Swoboda


Orphanet Journal of Rare Diseases | 2017

Spinocerebellar ataxia type 29 due to mutations in ITPR1: a case series and review of this emerging congenital ataxia

Jessica L. Zambonin; Allison Bellomo; David B. Everman; Lee M. Frazer; Michael T. Geraghty; Amy Harper; Julie R. Jones; Benjamin Kamien; Kristin D. Kernohan; Mary Kay Koenig; Elizabeth E. Palmer; Randal C. Richardson; Reeval Segel; Mark A. Tarnopolsky; Jason R. Vanstone; Melissa Gibbons; Abigail Collins; Brent L. Fogel; Tracy Dudding-Byth; Kym M. Boycott

Collaboration


Dive into the Abigail Collins's collaboration.

Top Co-Authors

Avatar

Suzanne D. DeBrosse

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Mary Kay Koenig

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amy Goldstein

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Andrea Gropman

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brent L. Fogel

University of California

View shared research outputs
Top Co-Authors

Avatar

Bruce H. Cohen

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Chad D. Huff

University of Texas MD Anderson Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge